DiaMedica Receives Phase I/II Clinical Trial Regulatory Approval for DM-199 as a Potential Treatment for Diabetes
08-Apr-2013 – Minneapolis, MN
DiaMedica Inc. (TSX-V:DMA), is pleased to announce it has received regulatory approval to commence an anticipated 76 subject Phase I/II clinical trial for DM-199. The clinical trial, to be conducted in the Netherlands, is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of DM-199 in 36 healthy volunteers and in 40 T2D patients. Data from this trial will also support future DM-199 clinical trial regulatory filings for Type 1 and 2 diabetes and in other potential indications.